Needham upgraded Amicus (FOLD) to Buy from Hold with a $14 price target The FDA’s decision to no longer require a panel meeting for Travere’s (TXTX) Filspari, coupled with last year’s Parasol recommendation and Dimerix’s prior Type C meeting with the FDA, indicate reduction in proteinuria is a suitable primary endpoint for full approval in focal segmental glomerulosclerosis, the analyst tells investors in a research note. The firm believes this lowers the regulatory risk for Amicus’ DMX-200. Despite DMX-200 being a Phase III program with peak sales potential of over $1.5B in the U.S., Amicus’ opportunity in FSGS is not priced into the stock, contends Needham.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on FOLD:
- Amicus Stock Upgraded to Buy: DMX-200’s Potential and Galafold’s Growth Drive Investment Opportunity
- Amicus upgraded to Buy from Hold at Needham
- Positive Outlook for Amicus Therapeutics Amid Legal Developments and Patent Confidence
- Jefferies says Galafold summary judgment as expected, may facilitate settlement
- Amicus presents four-year data from PROPEL study of Pombiliti, Opfolda